When Does Accommodation Work? Electoral Effects of Mainstream Left Position Taking on Immigration: Electoral Effects of Mainstream Left Position Taking on Immigration

Research output: Contribution to journalLetterResearchpeer-review

Standard

When Does Accommodation Work? Electoral Effects of Mainstream Left Position Taking on Immigration : Electoral Effects of Mainstream Left Position Taking on Immigration. / Hjorth, Frederik Georg; Larsen, Martin Vinæs.

In: British Journal of Political Science, Vol. 52, No. 2, 2021, p. 949-957.

Research output: Contribution to journalLetterResearchpeer-review

Harvard

Hjorth, FG & Larsen, MV 2021, 'When Does Accommodation Work? Electoral Effects of Mainstream Left Position Taking on Immigration: Electoral Effects of Mainstream Left Position Taking on Immigration', British Journal of Political Science, vol. 52, no. 2, pp. 949-957. https://doi.org/10.1017/S0007123420000563

APA

Hjorth, F. G., & Larsen, M. V. (2021). When Does Accommodation Work? Electoral Effects of Mainstream Left Position Taking on Immigration: Electoral Effects of Mainstream Left Position Taking on Immigration. British Journal of Political Science, 52(2), 949-957. https://doi.org/10.1017/S0007123420000563

Vancouver

Hjorth FG, Larsen MV. When Does Accommodation Work? Electoral Effects of Mainstream Left Position Taking on Immigration: Electoral Effects of Mainstream Left Position Taking on Immigration. British Journal of Political Science. 2021;52(2):949-957. https://doi.org/10.1017/S0007123420000563

Author

Hjorth, Frederik Georg ; Larsen, Martin Vinæs. / When Does Accommodation Work? Electoral Effects of Mainstream Left Position Taking on Immigration : Electoral Effects of Mainstream Left Position Taking on Immigration. In: British Journal of Political Science. 2021 ; Vol. 52, No. 2. pp. 949-957.

Bibtex

@article{f8d589cc06104b47bce58b854ff3074d,
title = "When Does Accommodation Work? Electoral Effects of Mainstream Left Position Taking on Immigration: Electoral Effects of Mainstream Left Position Taking on Immigration",
abstract = "Introduction: Oral mucositis is a painful side effect to chemotherapy. Orally applied opioids may offer analgesia with fewer side effects than systemic opioids. Methods: A randomized trial comparing the analgesic effect of a morphine oromucosal solution (OM) to placebo and a positive control group receiving intravenous (IV) morphine as an add-on treatment to morphine patient-controlled analgesia (PCA) in a mixed population of paediatric and adult haematology patients. All patients in the study were equipped with a morphine PCA pump and the participating patients were instructed to use this pump as an escape. Primary outcome was morphine consumption (mg/kg/hour) on the PCA pump. Secondary outcomes included pain intensity difference at rest and when performing oral hygiene, time to first PCA bolus, nutrition intake and adverse events.Findings: A total of 60 patients (38 children <18 years) were randomized. Thirty patients were allocated to morphine OM/placebo IV (group MO), 15 patients to placebo OM/morphine IV (group MI) and 15 patients to placebo OM/placebo IV (group P). The median morphine consumption in the MO group (22.7 mcg/kg/hour 95% confidence interval (CI) 19.4–29.4 mcg/kg/hour, p = 0.38) was not significantly different from the placebo group (24.6 mcg/kg/hour 95% CI 16.8–34.4 mcg/kg/hour, p = 0.44) or the MI group (13.7 mcg/kg/hour 95% CI 9.7–37.8 mcg/kg/hour). For the secondary outcomes, the analysis of summed pain intensity difference after the first, third and fourth administrations of study medication indicated a reduction in pain for the MI group compared to the P and MO groups. No serious adverse events were reported.Conclusion: The findings indicate that the analgesic effect of peripherally applied morphine is not significantly different from placebo, and parenteral opioids should continue to be the standard of care.",
author = "Hjorth, {Frederik Georg} and Larsen, {Martin Vin{\ae}s}",
year = "2021",
doi = "10.1017/S0007123420000563",
language = "English",
volume = "52",
pages = "949--957",
journal = "British Journal of Political Science",
issn = "0007-1234",
publisher = "Cambridge University Press",
number = "2",

}

RIS

TY - JOUR

T1 - When Does Accommodation Work? Electoral Effects of Mainstream Left Position Taking on Immigration

T2 - Electoral Effects of Mainstream Left Position Taking on Immigration

AU - Hjorth, Frederik Georg

AU - Larsen, Martin Vinæs

PY - 2021

Y1 - 2021

N2 - Introduction: Oral mucositis is a painful side effect to chemotherapy. Orally applied opioids may offer analgesia with fewer side effects than systemic opioids. Methods: A randomized trial comparing the analgesic effect of a morphine oromucosal solution (OM) to placebo and a positive control group receiving intravenous (IV) morphine as an add-on treatment to morphine patient-controlled analgesia (PCA) in a mixed population of paediatric and adult haematology patients. All patients in the study were equipped with a morphine PCA pump and the participating patients were instructed to use this pump as an escape. Primary outcome was morphine consumption (mg/kg/hour) on the PCA pump. Secondary outcomes included pain intensity difference at rest and when performing oral hygiene, time to first PCA bolus, nutrition intake and adverse events.Findings: A total of 60 patients (38 children <18 years) were randomized. Thirty patients were allocated to morphine OM/placebo IV (group MO), 15 patients to placebo OM/morphine IV (group MI) and 15 patients to placebo OM/placebo IV (group P). The median morphine consumption in the MO group (22.7 mcg/kg/hour 95% confidence interval (CI) 19.4–29.4 mcg/kg/hour, p = 0.38) was not significantly different from the placebo group (24.6 mcg/kg/hour 95% CI 16.8–34.4 mcg/kg/hour, p = 0.44) or the MI group (13.7 mcg/kg/hour 95% CI 9.7–37.8 mcg/kg/hour). For the secondary outcomes, the analysis of summed pain intensity difference after the first, third and fourth administrations of study medication indicated a reduction in pain for the MI group compared to the P and MO groups. No serious adverse events were reported.Conclusion: The findings indicate that the analgesic effect of peripherally applied morphine is not significantly different from placebo, and parenteral opioids should continue to be the standard of care.

AB - Introduction: Oral mucositis is a painful side effect to chemotherapy. Orally applied opioids may offer analgesia with fewer side effects than systemic opioids. Methods: A randomized trial comparing the analgesic effect of a morphine oromucosal solution (OM) to placebo and a positive control group receiving intravenous (IV) morphine as an add-on treatment to morphine patient-controlled analgesia (PCA) in a mixed population of paediatric and adult haematology patients. All patients in the study were equipped with a morphine PCA pump and the participating patients were instructed to use this pump as an escape. Primary outcome was morphine consumption (mg/kg/hour) on the PCA pump. Secondary outcomes included pain intensity difference at rest and when performing oral hygiene, time to first PCA bolus, nutrition intake and adverse events.Findings: A total of 60 patients (38 children <18 years) were randomized. Thirty patients were allocated to morphine OM/placebo IV (group MO), 15 patients to placebo OM/morphine IV (group MI) and 15 patients to placebo OM/placebo IV (group P). The median morphine consumption in the MO group (22.7 mcg/kg/hour 95% confidence interval (CI) 19.4–29.4 mcg/kg/hour, p = 0.38) was not significantly different from the placebo group (24.6 mcg/kg/hour 95% CI 16.8–34.4 mcg/kg/hour, p = 0.44) or the MI group (13.7 mcg/kg/hour 95% CI 9.7–37.8 mcg/kg/hour). For the secondary outcomes, the analysis of summed pain intensity difference after the first, third and fourth administrations of study medication indicated a reduction in pain for the MI group compared to the P and MO groups. No serious adverse events were reported.Conclusion: The findings indicate that the analgesic effect of peripherally applied morphine is not significantly different from placebo, and parenteral opioids should continue to be the standard of care.

U2 - 10.1017/S0007123420000563

DO - 10.1017/S0007123420000563

M3 - Letter

VL - 52

SP - 949

EP - 957

JO - British Journal of Political Science

JF - British Journal of Political Science

SN - 0007-1234

IS - 2

ER -

ID: 271758668